Immatics (IMTX) is a top German stock choice for hedge funds with growth potential

From Yahoo Finance: 2025-04-02 15:37:00

Germany’s economy faces continued weakness with a 0.1% contraction in 2023 and 0.2% in 2024, countered by a projected 0.4% growth in 2025. Manufacturing orders are recovering slightly but unemployment reached 2.81 million in December 2024. Inflation is expected to average 2% in 2025.
Chris Verrone expressed bullish outlook on the European market, emphasizing European industrials achieving new highs. European banks showed strength, but investors are still cautious. Verrone cited the German ETF EWG breaking a 20-year high. He noted bearishness towards European markets, with peripheral European markets leading.
Immatics (IMTX) is a clinical-stage biopharmaceutical company developing T-cell redirecting immunotherapies for cancer. Their primary growth driver is the ACTengine® IMA203 TCR-T cell therapy program targeting PRAME. Positive Phase 1b data shows promise in melanoma patients, with a BLA submission planned for Q1 2027. They also have $628 million in cash reserves.
IMTX ranks 2nd on the list of best German stocks to buy according to hedge funds. While IMTX shows growth potential, AI stocks offer high returns in a shorter time frame. For a promising AI stock trading at less than 5 times its earnings, a report is available on the cheapest AI stock.

Software stocks plummet due to AI concerns